US 11,718,593 B2
2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases
Mark J. Suto, Homewood, AL (US); Bini Mathew, Hoover, AL (US); Rita Cowell, Hoover, AL (US); and Corinne E. Augelli-Szafran, Homewood, AL (US)
Assigned to Southern Research Institute, Birmingham, AL (US)
Appl. No. 17/53,512
Filed by Southern Research Institute, Birmingham, AL (US)
PCT Filed May 16, 2019, PCT No. PCT/US2019/032658
§ 371(c)(1), (2) Date Nov. 6, 2020,
PCT Pub. No. WO2019/222497, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/673,112, filed on May 17, 2018.
Prior Publication US 2021/0246110 A1, Aug. 12, 2021
Int. Cl. C07D 277/42 (2006.01); C07D 277/22 (2006.01); C07D 277/30 (2006.01); C07D 317/58 (2006.01); C07D 417/10 (2006.01); C07D 417/14 (2006.01); A61P 25/28 (2006.01)
CPC C07D 277/42 (2013.01) [A61P 25/28 (2018.01); C07D 277/22 (2013.01); C07D 277/30 (2013.01); C07D 317/58 (2013.01); C07D 417/10 (2013.01); C07D 417/14 (2013.01)] 4 Claims
 
1. A compound having a structure represented by a formula:

OG Complex Work Unit Chemistry
wherein Ar1 is selected from monocyclic aryl and pyridinyl, and is substituted with 0, 1, or 2 groups independently selected from halogen, —CN, —NH2, —OH, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,
or a pharmaceutically acceptable salt thereof.